Novartis | NOVN - Umsatzkosten

Aktienkurs
122.10
Täglich Wechseln
-0.08 -0.07%
Monatlich
0.71%
Jährlich
41.83%
Q2 Prognose
120.10




Umsatzkosten Veränderung Datum
AbbVie USD 4.55B 757M 2025-12
Alcon AG USD 1.2B 46M 2025-12
Almirall EUR 191.5M 2.29M 2025-12
Amgen USD 1.79B 128M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
Autolus Therapeutics Ltd USD 25.33M 3.31M 2025-12
Bayer EUR 4.5B 194M 2025-12
Biogen USD 810.1M 205.1M 2025-09
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Fresenius EUR 4.45B 262M 2025-12
Fresenius Medical Care EUR 3.68B 38.37M 2025-12
Galapagos EUR 455K 84.28M 2025-12
Genmab DKK 81M 23M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
GRIFOLS EUR 1.29B 163.12M 2025-12
Hikma Pharmaceutical USD 959M 492.5M 2025-12
J&J USD 7.97B 689M 2025-12
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.29B 183M 2025-12
Merck USD 3.32B 531M 2025-12
Novartis USD 3.54B 3M 2025-12
Novartis USD 3.54B 7M 2025-12
Novo Nordisk DKK 15.15B 2.3B 2025-12
Orion EUR 186.6M 17.6M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Philips EUR 2.81B 417M 2025-12
Recordati EUR 199.91M 20.12M 2025-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 4.29B 421M 2025-12
UCB EUR 1.07B 146M 2025-12